Completed PHASE3 INTERVENTIONAL 2-arm NCT01256177

Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression

A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression

Sponsor: AstraZeneca

Conditions Bipolar Depression

Interventions Placebo Quetiapine Fumarate (SEROQUEL) Extended Release

Updated 6 times since 2017 Last updated: Mar 18, 2016 Started: Dec 31, 2010 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01256177, this PHASE3 trial focuses on Bipolar Depression and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2010, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baoding, China , Beijing, China , Changsha, China , Guangzhou, China , Hangzhou, China , Kunming, China , Nanjing, China , Shanghai, China , Shanxi, China , Tianjin, China and 2 more locations